文献速递眼底病与葡萄膜炎

动脉内化疗后眼球摘除的视网膜母细胞瘤组织病理学研究

Histopathology of retinoblastoma eyes enucleated after intra-arterial chemotherapy.
PubMed 文献 · Br J Ophthalmol · 2019-11-01

该回顾性研究纳入23只接受动脉内化疗(IAC)后摘除的视网膜母细胞瘤患眼,IAC一线治疗9眼、挽救治疗14眼,马法兰剂量3至7.5 mg、平均1.8个周期。摘除主因为治疗反应差或肿瘤进展14眼、严重血管并发症5眼、全渗出性视网膜脱离伴黑矇4眼;15眼有活动性疾病,4眼因高危转移因素需辅助化疗,截至研究时无转移。血管毒性包括视网膜中央动脉阻塞3眼、严重血管炎3眼、缺血性外层视网膜萎缩及脉络膜缺血7眼(其中1眼严重增殖性视网膜病变)。

要点

  • 23只IAC后摘除眼平均1.8个周期,马法兰剂量3至7.5 mg,2015年前未用严格年龄适配方案。
  • 摘除主因:治疗反应差或肿瘤进展14眼,严重血管并发症5眼,全渗出性视网膜脱离伴黑矇4眼。
  • 15眼有活动性疾病,4眼因高危转移因素需辅助化疗,截至研究时无转移。

核心结论

  • IAC是晚期视网膜母细胞瘤的高效治疗选择,但应警惕严重血管并发症及可能残留符合高危辅助化疗标准的存活肿瘤细胞。

研究设计与样本

  • 回顾性研究,连续纳入23只接受以马法兰行IAC后摘除、且有组织病理学检查的视网膜母细胞瘤患眼;IAC为一线治疗9眼、挽救治疗14眼。

主要发现

  • 马法兰剂量范围为3至7.5 mg,2015年前未采用严格年龄适配剂量方案,平均治疗周期数为1.8。
  • 摘除指征:治疗反应差或肿瘤进展14眼,严重血管并发症5眼,全渗出性视网膜脱离伴黑矇4眼。
  • 15眼存在活动性疾病,其中4眼因高危转移因素需辅助化疗,截至研究时无患者发生转移。
  • 血管毒性:视网膜中央动脉阻塞3眼,严重血管炎3眼,缺血性外层视网膜萎缩及脉络膜缺血7眼,其中1眼发生严重增殖性视网膜病变。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To demonstrate histopathological findings in retinoblastoma eyes enucleated after intra-arterial chemotherapy (IAC) with special emphasis on vascular toxicity and local tumour control. METHODS: Retrospective study with a consecutive series of 23 retinoblastoma eyes enucleated after IAC where histopathological work-up was available. RESULTS: From November 2010 to June 2019 23 eyes were enucleated after the attempt of eye salvaging therapy with IAC using melphalan. IAC was the first line treatment in nine and salvage treatment in 14 eyes. Doses of melphalan ranged from 3 to 7.5 mg, whereby a strict protocol with age-appropriate dosage was not used until 2015. The mean number of treatment cycles was 1.8. The main indications for enucleation were poor treatment response or tumour progression in 14 eyes, severe vascular complications in five eyes and a total exudative retinal detachment with amaurosis in the remaining four eyes. We found active disease in 15 eyes with an indication for adjuvant chemotherapy due to high risk factors for metastases in four eyes. To date none of these patients developed metastatic disease. Concerning vascular toxicity, we detected a central retinal artery occlusion in three eyes, severe vasculitis in another three, ischaemic outer retina atrophy and choroidal ischaemia in seven eyes with one eye developing a severe proliferative retinopathy. CONCLUSION: IAC is a highly effective treatment option for advanced retinoblastoma, but the described potential risks should be kept in mind. These include severe vascular complications, as well as the possibility of persisting vital tumour cells fulfilling high-risk criteria for adjuvant chemotherapy.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Biewald EM, Bornfeld N, Metz KA, et al. Histopathology of retinoblastoma eyes enucleated after intra-arterial chemotherapy. Br J Ophthalmol. 2019. PMID: 31676593. doi:10.1136/bjophthalmol-2019-315209

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。